期刊文献+

促性腺激素释放激素激动剂与米非司酮治疗子宫肌瘤的临床对照研究 被引量:90

A Clinical Control Study on the Treatment of Uterine Leiomyoma with Gonadotrophin Releasing Hormone Agonist or Mifepristone
原文传递
导出
摘要 目的比较促性腺激素释放激素激动剂(GnRH-a)与米非司酮治疗子宫肌瘤的临床疗效及副作用。方法将75例根据临床症状、妇科检查及B超诊断为子宫肌瘤患者,随机分为两组,GnRH-a组30例,每天用GnRH-a150μg肌内注射或皮下注射3个月;米非司酮组45例,用米非司酮每天12.5mg口服3个月,比较两组治疗的疗效与副反应。结果两组患者临床症状均有明显改善。肌瘤体积,GnRH-a组缩小20.0%以上者有27例,占90.0%;米非司酮组肌瘤缩小20.0%以上者有41例,占91.1%。复发率,GnRH-a组为40.0%,米非司酮组为17.8%。 Objective To compare the results and side effects in treating uterine leiomyoma with gonadotrophin releasing hormone agonist (GnRHa) or mifepristone. Methods 75 patients with uterine leiomyoma who had clinical symptoms and diagnosed by Bcan were divided into two groups. The GnRHa group (30 patients) was treated by injection of GnRHa 150 μg/day subcutaneously for three months, and the mifepristone group (45 patients) was treated by mifepristone 12.5 mg/day po for three months. Results The clinical symptoms improved obviously in both groups. The volume of leiomyoma reduced 20.0% or more in 90.0% (27/30) of the patients in GnRHa group, while it was 91.1% (41/45) in mifepristone group. However, the recurrent rates were 40.0% and 17.8% in the 2 groups. Conclusion It suggested that mifepristone is a more practical and hopeful drug in treating uterine leiomyoma.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 1998年第8期490-492,共3页 Chinese Journal of Obstetrics and Gynecology
关键词 子宫肿瘤 平滑肌瘤 GNRH-Α 米非司酮 药物疗法 Uterine neoplasms Leiomyoma Gonadorelin Mifepristone
  • 引文网络
  • 相关文献

参考文献5

  • 1钟蕙芳,实用妇产科杂志,1997年,13卷,148页
  • 2张俊慧,实用妇产科杂志,1995年,11卷,35页
  • 3尚丽新,中华妇产科杂志,1995年,30卷,233页
  • 4廖爱华,实用妇产科杂志,1994年,10卷,15页
  • 5陆湘云,促性腺激素释放激素及其类似物在妇产科的应用,1994年,109页

同被引文献526

引证文献90

二级引证文献607

;
使用帮助 返回顶部